Biogen Company Insiders

BIIB Stock  USD 201.99  8.81  4.56%   
About 89 percent of Biogen's insiders are activelly selling. The analysis of the overall insider sentiment regarding Biogen Inc suggests that quite a large number of insiders are panicking. Biogen employs about 7.6 K people. The company is managed by 50 executives with a total tenure of roughly 396 years, averaging almost 7.0 years of service per executive, having 151.4 employees per reported executive.
George Scangos  CEO
CEO and Director
Stelios Papadopoulos  Chairman
Independent Chairman of the Board

Biogen's Insider Buying Vs Selling

11

 
Selling
 
Buying

Latest Trades

2024-04-02Priya SinghalDisposed 93 @ 213.09View
2024-02-22Priya SinghalDisposed 262 @ 221.23View
2024-02-16Priya SinghalDisposed 108 @ 221.49View
2024-02-15Eric K RowinskyAcquired 455 @ 222.54View
2024-02-12Priya SinghalDisposed 419 @ 239.45View
2023-12-11Priya SinghalDisposed 110 @ 248View
2023-09-05Priya SinghalDisposed 431 @ 269.43View
2023-07-03Priya SinghalDisposed 81 @ 282.87View
2023-04-28Ginger GregoryDisposed 2681 @ 300View
Monitoring Biogen's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

Biogen's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Biogen's future performance. Based on our forecasts, it is anticipated that Biogen will maintain a workforce of about 7570 employees by May 2024.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Biogen's latest congressional trading

Congressional trading in companies like Biogen Inc, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Biogen by those in governmental positions are based on the same information available to the general public.
2023-03-06Representative Daniel GoldmanAcquired Under $15KVerify
2023-01-23Representative Shri ThanedarAcquired $15K to $50KVerify
2022-08-03Representative Kathy ManningAcquired Under $15KVerify
2022-03-17Representative Josh GottheimerDisposed Under $15KVerify
2021-02-16Representative Peter MeijerAcquired $15K to $50KVerify
2021-01-04Representative Chris JacobsDisposed Under $15KVerify
2020-12-22Representative Gilbert CisnerosAcquired Under $15KVerify
2019-06-24Representative Donna ShalalaAcquired Under $15KVerify
2019-06-20Representative Dean PhillipsAcquired Under $15KVerify
2019-03-22Senator Sheldon WhitehouseAcquired Under $15KVerify
2016-07-21Senator James M. InhofeAcquired $50K to $100KVerify
2014-07-23Senator Susan M CollinsAcquired Under $15KVerify
2014-07-23Senator Susan M. CollinsAcquired Under $15KVerify

Biogen Management Team Effectiveness

The company has return on total asset (ROA) of 0.0458 % which means that it generated a profit of $0.0458 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0824 %, meaning that it created $0.0824 on every $100 dollars invested by stockholders. Biogen's management efficiency ratios could be used to measure how well Biogen manages its routine affairs as well as how well it operates its assets and liabilities. At present, Biogen's Return On Capital Employed is projected to increase slightly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.06, whereas Return On Tangible Assets are forecasted to decline to 0.08. At present, Biogen's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 21 B, whereas Non Currrent Assets Other are forecasted to decline to about 270.1 M.
The current year's Common Stock Shares Outstanding is expected to grow to about 283 M, whereas Net Income Applicable To Common Shares is forecasted to decline to about 2 B.

Biogen Workforce Comparison

Biogen Inc is number one stock in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 8,285. Biogen totals roughly 7,570 in number of employees claiming about 91% of equities under Health Care industry.

Biogen Profit Margins

The company has Profit Margin (PM) of 0.12 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.19 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.19.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.510.7424
Way Down
Slightly volatile

Biogen Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biogen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biogen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Biogen insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-06-01
0.3333
1
3
 240.00 
 450.00 
2024-03-01
0.6765
46
68
 139,080 
 78,748 
2023-12-01
0.5
3
6
 2,862 
 1,263 
2023-09-01
0.3333
3
9
 6,953 
 13,739 
2023-06-01
1.1
11
10
 11,226 
 4,362 
2023-03-01
0.5152
34
66
 80,501 
 66,488 
2022-12-01
0.6667
8
12
 216,273 
 14,720 
2022-09-01
0.4615
6
13
 6,582 
 12,893 
2022-06-01
5.5
11
2
 14,824 
 323.00 
2022-03-01
0.5143
36
70
 133,077 
 106,990 
2021-12-01
0.5
4
8
 1,763 
 1,564 
2021-09-01
1.5
15
10
 16,056 
 12,481 
2021-03-01
0.5484
34
62
 200,073 
 101,781 
2020-12-01
0.375
3
8
 3,655 
 3,434 
2020-09-01
0.8
4
5
 25,102 
 651.00 
2020-03-01
0.5
34
68
 157,453 
 97,036 
2019-12-01
0.25
2
8
 627.00 
 2,815 
2019-09-01
0.2222
2
9
 375.00 
 2,052 
2019-06-01
2.1111
19
9
 141,064 
 7,372 
2019-03-01
0.5538
36
65
 235,304 
 102,720 
2018-12-01
0.2857
4
14
 1,999 
 4,036 
2018-09-01
0.4
2
5
 2,022 
 1,589 
2018-06-01
1.625
13
8
 60,441 
 7,564 
2018-03-01
0.6038
32
53
 142,851 
 57,041 
2017-12-01
1.0
7
7
 41,905 
 1,007 
2017-09-01
1.3333
4
3
 7,733 
 12,732 
2017-06-01
1.5455
17
11
 91,600 
 20,006 
2017-03-01
0.507
36
71
 110,669 
 76,577 
2016-12-01
0.1818
2
11
 2,912 
 9,064 
2016-09-01
0.4
2
5
 27,570 
 55,207 
2016-06-01
0.9444
17
18
 42,414 
 12,683 
2016-03-01
0.4712
49
104
 192,450 
 141,920 
2015-12-01
0.4
4
10
 312,422 
 7,667 
2015-06-01
0.8333
15
18
 14,360 
 21,055 
2015-03-01
0.4468
63
141
 266,140 
 310,059 
2014-12-01
0.3333
3
9
 21,297 
 10,723 
2014-09-01
0.125
1
8
 21,339 
 46,773 
2014-06-01
0.9375
15
16
 27,547 
 22,845 
2014-03-01
0.4083
49
120
 258,976 
 307,896 
2013-12-01
0.1429
2
14
 19,030 
 46,571 
2013-09-01
0.2
9
45
 160,974 
 337,546 
2013-06-01
0.3704
20
54
 112,087 
 287,983 
2013-03-01
0.5
39
78
 269,811 
 255,163 
2012-12-01
0.1111
1
9
 5,378 
 24,862 
2012-09-01
0.2941
5
17
 89,409 
 189,287 
2012-06-01
0.7188
23
32
 146,304 
 301,555 
2012-03-01
0.4857
34
70
 256,668 
 247,302 
2011-12-01
0.1538
2
13
 2,953 
 18,407 
2011-09-01
0.3929
11
28
 114,591 
 264,293 
2011-06-01
0.4324
16
37
 105,625 
 204,891 
2011-03-01
0.3671
29
79
 266,304 
 178,125 
2010-12-01
0.2105
4
19
 56,350 
 128,728 
2010-09-01
0.087
2
23
 148,523 
 118,459 
2010-06-01
0.7222
13
18
 1,240,164 
 1,247,712 
2010-03-01
0.5
20
40
 716,886 
 960,106 
2009-12-01
0.125
1
8
 1,000.00 
 154,308 
2009-06-01
2.3333
14
6
 132,720 
 6,147 
2009-03-01
0.6071
17
28
 381,916 
 112,620 
2008-12-01
0.125
1
8
 1,000.00 
 9,218 
2008-09-01
0.7727
17
22
 254,361 
 334,911 
2008-06-01
0.0488
10
205
 774,250 
 1,525,920 
2008-03-01
0.1264
23
182
 600,854 
 167,192 
2007-12-01
0.1538
8
52
 147,100 
 232,318 
2007-09-01
0.5
23
46
 518,732 
 1,081,470 
2007-06-01
1.25
5
4
 15,550 
 8,981 
2007-03-01
0.9394
31
33
 808,143 
 289,177 
2006-12-01
0.1951
8
41
 526,500 
 1,002,210 
2006-09-01
0.1622
6
37
 162,500 
 193,006 
2006-06-01
0.5294
9
17
 76,175 
 117,350 
2006-03-01
2.4
24
10
 854,400 
 319,500 
2005-12-01
0.12
3
25
 98,042 
 195,898 
2005-09-01
0.0364
2
55
 20,500 
 126,125 
2005-06-01
0.0345
1
29
 20,500 
 41,000 
2005-03-01
0.4182
23
55
 1,199,188 
 572,794 
2004-12-01
0.3208
34
106
 189,743 
 527,772 
2004-09-01
0.2929
29
99
 204,519 
 401,361 
2004-06-01
0.4132
50
121
 933,599 
 1,181,091 
2004-03-01
3.6
18
5
 736,552 
 32,814 
2003-12-01
2.35
47
20
 3,230,135 
 187,458 

Biogen Notable Stakeholders

A Biogen stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Biogen often face trade-offs trying to please all of them. Biogen's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Biogen's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Christopher ViehbacherCEO PresidentProfile
George ScangosCEO and DirectorProfile
Stelios PapadopoulosIndependent Chairman of the BoardProfile
Robin KramerChief Accounting Officer, Vice PresidentProfile
Paul McKenzieExecutive Vice President - Pharmaceutical Operations & TechnologyProfile
Alfred SandrockGroup Senior Vice President Chief Medical OfficerProfile
Spyros ArtavanisTsakonasSenior Vice President Chief Scientific OfficerProfile
JeanPaul KressExecutive Vice President and Presidentident - International and Head of Global Therapeutic OperationsProfile
Kenneth PietroExecutive Vice President - Human ResourcesProfile
Adam KoppelSenior Vice President and Chief Strategy OfficerProfile
Michael EhlersExecutive Vice President of Research and DevelopmentProfile
Ginger GregoryChief Human Resource Officer, Executive Vice PresidentProfile
Daniel KarpExecutive Vice President - Corporate DevelopmentProfile
Anirvan GhoshSenior Vice President - Research and Early DevelopmentProfile
Anabella VillalobosSenior Vice President - Biotherapeutic & Medicinal Sciences (BTMS)Profile
Matt GriffithsSenior Vice President CIOProfile
Jeffrey CapelloCFO, Executive Vice PresidentProfile
Michel VounatsosVice President and Chief Commercial OfficerProfile
Sanjay JariwalaSenior Vice President - Worldwide MedicalProfile
Mark HernonSenior Vice President CIOProfile
Chirfi GuindoExecutive Vice President Head of Global Marketing, Market Access and Customer InnovationProfile
Susan AlexanderExecutive Vice President Chief Legal Officer and Corporate SecretaryProfile
Catherine SteeleSenior Vice President - Corporate AffairsProfile
Steven HoltzmanExecutive Vice President - Corporate DevelopmentProfile
Camille LeeSenior Vice President - Alzheimer's Therapeutic AreaProfile
Alisha AlaimoPresident AmericaProfile
Michael CPAExecutive CFOProfile
Paul ClancyCFO and Executive VP of Fin.Profile
Douglas WilliamsExecutive VP of RandDProfile
Adriana KaraboutisExecutive VP of Technology, Bus. Solutions and Corporate AffairsProfile
John CoxExecutive VP of Pharmaceutical Operations and TechnologyProfile
Alexander DennerIndependent DirectorProfile
Eric RowinskyIndependent DirectorProfile
William HawkinsDirectorProfile
John ChiminskiDirectorProfile
Caroline DorsaIndependent DirectorProfile
Robert PangiaIndependent DirectorProfile
Jesus MantasDirectorProfile
Richard MulliganIndependent DirectorProfile
Stephen SherwinIndependent DirectorProfile
Nancy LeamingIndependent DirectorProfile
Lynn SchenkIndependent DirectorProfile
Brian PosnerIndependent DirectorProfile
Gregory CovinoChief Accounting Officer, VP of Fin. and ControllerProfile
Natacha GassenbachChief AffairsProfile
Charles TrianoSenior RelationsProfile
Adam KeeneyExecutive DevelopmentProfile
Susan EsqExecutive OfficerProfile
Nicole MurphyHead TechnologyProfile
Michael HenckeHead RelationsProfile

About Biogen Management Performance

The success or failure of an entity such as Biogen Inc often depends on how effective the management is. Biogen management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Biogen management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Biogen management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.09  0.08 
Return On Capital Employed 0.06  0.08 
Return On Assets 0.04  0.06 
Return On Equity 0.08  0.1 
The data published in Biogen's official financial statements usually reflect Biogen's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Biogen Inc. For example, before you start analyzing numbers published by Biogen accountants, it's critical to develop an understanding of what Biogen's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Biogen's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biogen's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Biogen's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Biogen Inc. Please utilize our Beneish M Score to check the likelihood of Biogen's management manipulating its earnings.

Biogen Workforce Analysis

Traditionally, organizations such as Biogen use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Biogen within its industry.

Biogen Manpower Efficiency

Return on Biogen Manpower

Revenue Per Employee1.3M
Revenue Per Executive196.7M
Net Income Per Employee153.4K
Net Income Per Executive23.2M
Working Capital Per Employee452.4K
Working Capital Per Executive68.5M
When determining whether Biogen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biogen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biogen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biogen Inc Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Complementary Tools for Biogen Stock analysis

When running Biogen's price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Is Biogen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biogen. If investors know Biogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.55)
Earnings Share
7.98
Revenue Per Share
67.972
Quarterly Revenue Growth
(0.06)
Return On Assets
0.0458
The market value of Biogen Inc is measured differently than its book value, which is the value of Biogen that is recorded on the company's balance sheet. Investors also form their own opinion of Biogen's value that differs from its market value or its book value, called intrinsic value, which is Biogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biogen's market value can be influenced by many factors that don't directly affect Biogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.